高危局限性和局部进展性前列腺癌的雄激素剥夺治疗
Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer.
作者信息
Iwamoto Hiroaki, Izumi Kouji, Makino Tomoyuki, Mizokami Atsushi
机构信息
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-Machi, Kanazawa 920-8640, Ishikawa, Japan.
Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa 920-8530, Ishikawa, Japan.
出版信息
Cancers (Basel). 2022 Apr 1;14(7):1803. doi: 10.3390/cancers14071803.
Abstract
The recommended treatment for high-risk localized or locally advanced prostate cancer is radical prostatectomy plus extended pelvic lymph node dissection or radiation therapy plus long-term androgen deprivation therapy. However, some patients are treated with androgen deprivation therapy alone for various reasons. In this review, we will discuss the position, indications, complications, and future prospects of androgen deprivation therapy for high-risk localized and locally advanced prostate cancer.
摘要
高危局限性或局部晚期前列腺癌的推荐治疗方法是根治性前列腺切除术加扩大盆腔淋巴结清扫术或放射治疗加长期雄激素剥夺治疗。然而，由于各种原因，一些患者仅接受雄激素剥夺治疗。在本综述中，我们将讨论雄激素剥夺治疗在高危局限性和局部晚期前列腺癌治疗中的地位、适应症、并发症及未来前景。
相似文献
1
Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer.高危局限性和局部进展性前列腺癌的雄激素剥夺治疗
Cancers (Basel). 2022 Apr 1;14(7):1803. doi: 10.3390/cancers14071803.
2
[Radiation therapy of locally advanced prostate cancer].[局部晚期前列腺癌的放射治疗]
Urologe A. 2017 Nov;56(11):1402-1409. doi: 10.1007/s00120-017-0511-4.
3
Laparoscopic Radical Prostatectomy Plus Extended Lymph Node Dissection in Combination With Immediate Androgen Deprivation Therapy for Cases of pT3-4N0-1M0 Prostate Cancer: A Multimodal Study of 8 Years' Follow-up.腹腔镜根治性前列腺切除术联合扩大淋巴结清扫术并立即进行雄激素剥夺治疗用于pT3-4N0-1M0前列腺癌病例：一项8年随访的多模式研究
Clin Genitourin Cancer. 2016 Aug;14(4):e321-7. doi: 10.1016/j.clgc.2015.11.009. Epub 2015 Nov 18.
4
SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer.SPCG - 15：一项比较局部晚期前列腺癌的根治性前列腺切除术与根治性放疗加雄激素剥夺治疗的前瞻性随机研究。
Scand J Urol. 2018 Oct-Dec;52(5-6):313-320. doi: 10.1080/21681805.2018.1520295. Epub 2018 Dec 26.
5
[Locally advanced prostate cancer: definition, prognosis and treatment].[局部晚期前列腺癌：定义、预后与治疗]
Bull Cancer. 2007 Jul;94(7 Suppl):F50-61.
6
Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.雄激素剥夺疗法治疗局部晚期、非转移性前列腺癌：实践经验及临床试验证据综述
Ther Adv Urol. 2017 Mar 1;9(3-4):73-80. doi: 10.1177/1756287217697661. eCollection 2017 Mar-Apr.
7
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
8
Treatment of locally advanced prostate cancer (Stage T3).局部晚期前列腺癌（T3期）的治疗
Jpn J Clin Oncol. 2017 Mar 1;47(3):257-261. doi: 10.1093/jjco/hyw186.
9
[Evaluation of immediate androgen deprivation adjuvant therapy in patients with lymph node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy].[前列腺癌根治术及盆腔淋巴结清扫术后淋巴结阳性患者即刻雄激素剥夺辅助治疗的评估]
Nihon Hinyokika Gakkai Zasshi. 2009 Jul;100(5):570-5. doi: 10.5980/jpnjurol.100.570.
10
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.高风险局限性和局部进展性前列腺癌的主要治疗方法的获益与风险：一项国际多学科系统评价。
Eur Urol. 2020 May;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Epub 2020 Mar 4.
引用本文的文献
1
Ginsenoside Rh2 repressed the progression of prostate cancer through the mitochondrial damage induced by mitophagy and ferroptosis.人参皂苷Rh2通过线粒体自噬和铁死亡诱导的线粒体损伤抑制前列腺癌的进展。
Front Oncol. 2025 Aug 21;15:1633891. doi: 10.3389/fonc.2025.1633891. eCollection 2025.
2
Deciphering the Tumor Microenvironment in Prostate Cancer: A Focus on the Stromal Component.解析前列腺癌中的肿瘤微环境：聚焦于基质成分。
Cancers (Basel). 2024 Oct 31;16(21):3685. doi: 10.3390/cancers16213685.
3
Comparison of the efficacy and safety profiles of generic and branded leuprorelin acetate microspheres in patients with prostate cancer.前列腺癌患者中，仿制和品牌醋酸亮丙瑞林微球的疗效和安全性比较。
Oncol Lett. 2024 May 14;28(1):319. doi: 10.3892/ol.2024.14452. eCollection 2024 Jul.
4
Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran.在伊朗，比较恩杂鲁胺和阿比特龙治疗去势抵抗性转移性前列腺癌的成本效果和预算影响分析。
BMC Urol. 2024 Feb 20;24(1):45. doi: 10.1186/s12894-024-01431-w.
5
Editorial for the Special Issue on High-Risk Localized and Locally Advanced Prostate Cancer.高危局限性和局部晚期前列腺癌特刊社论
Cancers (Basel). 2023 Jun 11;15(12):3153. doi: 10.3390/cancers15123153.
6
The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.雄激素受体靶向蛋白水解靶向嵌合体及其他治疗选择在克服前列腺癌雄激素剥夺治疗耐药中的作用。
Clin Transl Oncol. 2023 Feb;25(2):352-363. doi: 10.1007/s12094-022-02957-x. Epub 2022 Oct 6.
本文引用的文献
1
Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer - Narrowing the Gap Between Bench and Bedside.血管生成作为转移性前列腺癌的治疗靶点——缩小基础研究与临床治疗之间的差距。
Front Immunol. 2022 Feb 10;13:842038. doi: 10.3389/fimmu.2022.842038. eCollection 2022.
2
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙和泼尼松与或不与恩扎卢胺用于高危非转移性前列腺癌：来自 STAMPEDE 平台方案两项随机对照 3 期试验主要结果的荟萃分析。
Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23.
3
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.地加瑞克与亮丙瑞林治疗晚期前列腺癌的心血管安全性：PRONOUNCE试验研究设计
JACC CardioOncol. 2020 Mar 17;2(1):70-81. doi: 10.1016/j.jaccao.2020.01.004. eCollection 2020 Mar.
4
Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer.雄激素剥夺疗法与前列腺癌男性患痴呆症风险之间的关联。
Cancers (Basel). 2021 Jul 31;13(15):3861. doi: 10.3390/cancers13153861.
5
Exercise vs Conventional Treatment for Treatment of Primary Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.运动与常规治疗治疗原发性骨质疏松症的比较：随机对照试验的系统评价和荟萃分析。
Orthop Surg. 2021 Jul;13(5):1474-1487. doi: 10.1111/os.13036. Epub 2021 Jun 14.
6
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.阿帕鲁胺治疗转移性去势敏感性前列腺癌患者的生存分析：随机、双盲、III 期 TITAN 研究的最终生存分析。
J Clin Oncol. 2021 Jul 10;39(20):2294-2303. doi: 10.1200/JCO.20.03488. Epub 2021 Apr 29.
7
Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy.卡巴他赛起始时的肌肉减少症和内脏转移预测接受卡巴他赛化疗的去势抵抗性前列腺癌患者的预后。
In Vivo. 2021 May-Jun;35(3):1703-1709. doi: 10.21873/invivo.12430.
8
Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer.经典激素治疗作为非转移性去势抵抗性前列腺癌的雄激素剥夺治疗的有效性。
In Vivo. 2021 Mar-Apr;35(2):1247-1252. doi: 10.21873/invivo.12375.
9
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
10
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
Zotero 插件